Are Research Peptides Legal in 2026? The FDA Update Explained

Few questions show up in our inbox more often than this one. A researcher reads about BPC-157 or semaglutide, finds a US supplier, and pauses at checkout. Is this actually legal? Did the FDA ban these compounds? Will customs seize the package?

The short answer is reassuring. The long answer matters, because the difference between a legitimate research purchase and a compliance violation comes down to a few specific things — labeling, intended use, and how the product is marketed.

This article is informational and is not legal advice. Researchers and businesses with specific compliance questions should consult an attorney familiar with FDA and FTC regulations.

The legal framework: where research peptides actually sit

Research peptides exist in a category that confuses people because it spans three different bodies of law: the Federal Food, Drug, and Cosmetic Act (FDCA), the Dietary Supplement Health and Education Act of 1994 (DSHEA), and the FDA's rules on compounding pharmacies. None of these laws ban the sale of peptide compounds for laboratory research.

Here is what the framework actually says:

• FDA jurisdiction covers drugs, devices, food, and supplements intended for human or animal use. A peptide sold for laboratory research — clearly labeled, not marketed for consumption — generally falls outside the FDA's drug approval process, the same way a chemistry reagent does.
• DSHEA governs what can be sold as a dietary supplement. Most research peptides do not qualify as supplements (they are not vitamins, minerals, herbs, amino acids, or grandfathered ingredients), which is why no legitimate vendor markets them as such.
• DEA scheduling does not apply. Peptides like BPC-157, TB-500, semaglutide, and tirzepatide are not controlled substances. There is no schedule, no quota, no prescription requirement at the federal level for the compounds themselves as research chemicals.

The phrase "research use only" (RUO) is not marketing fluff. It is a regulatory designation. When a supplier labels a vial RUO and the buyer is purchasing it for non-clinical, non-human, in-vitro or animal model research, the transaction sits in a recognized commercial category alongside antibodies, reagents, and other lab compounds.

What "research use only" does not do is launder a product into legality if the seller is actually marketing it for human consumption. A vendor who slaps an RUO sticker on a vial while running ads about weight loss, recovery, or anti-aging is in clear violation regardless of the label.

What the 2023 FDA reclassification actually changed

In 2023, the FDA moved BPC-157 and several other peptides — including ipamorelin, CJC-1295, AOD-9604, and others — from Category 1 to Category 2 on the agency's list of bulk drug substances used in compounding under Section 503A of the FDCA.

This change is widely misunderstood. It is the single biggest source of "are peptides illegal now?" search traffic. Here is what it actually means.

Category 1 substances are eligible to be used by compounding pharmacies to prepare patient-specific prescriptions. Category 2 substances have been flagged by the FDA for safety concerns — typically immunogenicity, lack of human safety data, or insufficient established use — and are not eligible for compounding under 503A.

The practical effect of the 2023 reclassification:

• Compounding pharmacies can no longer legally prepare BPC-157 (and other Category 2 peptides) as a custom prescription for human patients. Many compounding pharmacies stopped offering these compounds in late 2023 and early 2024.
• Telehealth clinics that previously sourced through compounding pharmacies had to either remove these peptides from their menus or find another sourcing path (some did neither, which is a separate enforcement issue).
• Research suppliers were not affected by the rule itself. The Section 503A list governs compounding for human prescription use, not the sale of bulk research chemicals to laboratories.

The FDA's stated reasons for the Category 2 designation were not "this compound is dangerous." They were closer to "we don't have enough human safety data to clear this for compounded prescriptions, and there are questions about immunogenicity at scale." That is a regulatory caution applied to one specific commercial pathway. It does not retroactively criminalize the research market.

State-by-state: federal preemption and the disclosure layer

Research peptides are governed primarily at the federal level. There is no state in 2026 where buying research peptides from a US supplier for laboratory use is illegal at the state level. That said, a few states have layered on consumer-protection and disclosure requirements that affect how suppliers ship and label.

State	Additional requirement	Affects buyers?
California	Proposition 65 disclosure on certain compounds; "research use only" must appear on packaging visible at point of sale	Minor — adds disclosure language
New York	General Business Law disclosure rules on lab chemicals shipped to consumers	Minor
Florida	No additional research-chemical layer beyond federal	None
Texas	No additional research-chemical layer beyond federal	None
Most other states	Default to federal framework	None

The state-level layer is almost entirely about disclosure and consumer protection, not prohibition. A California researcher and a Texas researcher can both legally buy BPC-157 for research from a US supplier in 2026. The California buyer will simply see one or two extra disclosure lines on the packaging.

A handful of municipal jurisdictions have considered local rules on specific compounds (more often around GLP-1 agonists due to the patent-enforcement and counterfeit issues), but none have created broad research-peptide restrictions.

What's specifically NOT legal

This is where the question gets sharper. The research market is legal. Several adjacent activities are not. Researchers and suppliers both need to understand the lines.

Most of what people worry about when they ask "is this legal" is not actually about the compound. It is about whether the supplier is operating cleanly on the marketing and labeling side. A research peptide is a research peptide. A vendor making weight-loss claims about a research peptide is a vendor with a compliance problem.

WADA and competitive sports: a separate question entirely

This trips up athletes constantly, so it deserves its own section.

The legality of buying a research peptide for laboratory research and the eligibility of that compound for competitive sport are two unrelated questions. Most research peptides — including BPC-157, TB-500, ipamorelin, CJC-1295, GHRP-6, and the GLP-1 agonists — are on the World Anti-Doping Agency (WADA) prohibited list. They are also banned by USADA (US Anti-Doping Agency), the NCAA, most professional leagues, and most weightlifting federations.

A research-use purchase is not a defense in an anti-doping proceeding. If a sample tests positive, the athlete is responsible regardless of how the compound entered their system or what the label said. Researchers who also compete in tested sport should treat this as a hard line.

This is not a legal issue in the criminal sense — WADA rules are private contractual rules of competition — but it is a real consequence that gets overlooked.

How to verify a supplier operates legally

If you are buying for research, the legitimacy of your supplier is what determines your compliance position. A clean supplier looks like this:

1. US business address. A real, physical, verifiable address. Not a UPS Store, not a foreign drop-shipper, not a PO box. The address should appear in WHOIS records, on the contact page, and on the shipping label.
2. Clear "research use only" labeling. On the vial, on the box, on the website. Consistent across surfaces. No mixed messaging where the label says RUO but the homepage talks about benefits.
3. No health claims in marketing. A compliant supplier sells the chemistry — purity, COA, batch testing — not the outcome. If product pages read like a medical brochure, that is a flag.
4. Batch-specific COAs. A Certificate of Analysis tied to the specific lot you are buying. HPLC purity, mass spec confirmation, batch ID matching the vial. Generic COAs that look the same for every product are nearly worthless from a compliance standpoint.
5. Domestic shipping. Ships from a US warehouse to US customers. Avoids the customs uncertainty that hits international shipments.
6. Payment infrastructure that legitimate businesses use. Credit card acceptance through a real processor signals that the supplier has cleared underwriting. Crypto-only operations may be perfectly fine, but they are also the easiest setup for a vendor that wants to disappear.
7. A WHOIS history longer than the business claims to exist. A site claiming "15 years in research peptides" with a domain registered last quarter is misrepresenting itself.

None of these are legal requirements imposed on the buyer. They are signals that the supplier is operating in a way that holds up to scrutiny. The cleaner the supplier, the lower the chance of customs problems, the lower the chance of a vendor disappearing with your money, and the lower the chance of buying something that does not match the label.

The 2026 landscape: what's changed

The most discussed event in the research peptide market over the past year was the voluntary shutdown of Peptide Sciences in March 2026. This generated a wave of "is the FDA cracking down?" speculation in the community. The reality, based on public statements and industry reporting, is that the shutdown was a voluntary business decision driven by unrelated factors — not an enforcement action.

Several established suppliers are continuing to operate. New entrants — including third-party-tested specialists — are filling the gap left by Peptide Sciences. The COA standards in the market have, if anything, gotten tighter. Independent labs (Janoshik, Peptide Test, Finnrick) are testing more batches and publishing more results than they did two years ago. Buyers have better verification tools now than at any point in the last decade.

What has not changed:

• The federal legality of research peptides for laboratory use.
• The Category 2 reclassification from 2023 (still in effect, still about compounding pharmacies, still does not affect research suppliers).
• The basic compliance posture — RUO labeling, no health claims, domestic shipping.

What is worth watching:

• Continued state-level disclosure expansion (California is the bellwether).
• Patent enforcement on GLP-1 compounds, which is reshaping which vendors carry tirzepatide and semaglutide.
• Possible future FDA action on specific peptides if new safety data emerges, but no announced rulemaking targets the research market itself.

Bottom line

Researchers in the United States can legally purchase research peptides from US suppliers for laboratory use. The compounds are not scheduled, not banned, and not subject to FDA drug approval requirements when sold and labeled as research chemicals. The 2023 reclassification of BPC-157 and other peptides into Category 2 affects compounding pharmacies preparing prescriptions for patients — it does not affect the research market.

The compliance burden sits primarily on suppliers: clean labeling, no health claims, domestic operations, proper COAs. Buyers who source from suppliers that meet that bar are in a defensible position. Buyers who source from vendors making weight-loss claims, shipping from overseas without paperwork, or playing label games are not.

ROEHN Research operates as a research compound supplier with US business operations, "research use only" labeling, and batch-specific third-party COAs. The verification signals above are not theoretical — they are the same checklist we apply when evaluating every supplier covered in our reviews.

2026 Evaluation

9.6/10

Top-Ranked 2026 Supplier

The top-ranked supplier in our 2026 evaluation

ROEHN Research tested at 99.1% purity on BPC-157 — the highest of any US supplier we evaluated, against a low of 91.3%. Readers save 15% on a first order with code FREE15.

View ROEHN Research→

Save 15% with code FREE15

• Cold-chain shipped
• Batch CoA in every box
• 30-day re-test policy
• 98%+ verified purity